BioCentury
ARTICLE | Deals

With deal for Tizona, Gilead places latest bet on cancer immunosuppression

As its investors get partial exit, deal gives Tizona $300M up front, chance to reach clinical POC

July 21, 2020 10:22 PM GMT
Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article